Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4439941 | 0.88 | MEN1 (0.52) | CYP3A4CYP2D6CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL15268978 | 0.87 | CYP3A4 (0.55) | CYP3A4CYP2D6CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL2672901 | 0.85 | MEN1 (0.56) | CYP3A4CYP2D6CYP2C19MEN1KMT2A | |
| SCHEMBL18084753 | 0.85 | MEN1 (0.58) | CYP2C19MEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL16903356 | 0.84 | MEN1 (0.51) | CYP2C19MEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL17518850 | 0.83 | CYP3A4 (0.69) | CYP3A4CYP2D6CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL18084781 | 0.83 | MEN1 (0.50) | CYP2C19MEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL16979283 | 0.83 | CYP3A4 (0.51) | CYP3A4CYP2D6CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL22482797 | 0.83 | MEN1 (0.56) | CYP2D6CYP2C19CYP2C9MEN1KMT2A | |
| SCHEMBL14801782 | 0.83 | MEN1 (0.56) | CYP2D6CYP2C19CYP2C9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2025-08-26 | — | — | US | disclosed |
| EP-4262807-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| CN-116829151-A | Azaquinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230072276-A1 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. | 2023-03-09 | — | — | US | disclosed |
| WO-2022132200-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230072276-A1 | Azaquinazoline pan-KRas inhibitors | KRAS, NRAS, HRAS | CYP3A4 3117/4885CYP2D6 3574/4885CYP1A2 4465/4885 |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | KRAS, NRAS, HRAS | CYP3A4 3117/4885CYP2D6 3574/4885CYP1A2 4465/4885 |
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | CYP3A4 2558/4885CYP2D6 2545/4885CYP1A2 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.